echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Lilly releases new coronavirus and antibody Phase II proof-of-concept data: reducing the risk of hospitalization in outpatient COVID-19 patients by 72%.

    Lilly releases new coronavirus and antibody Phase II proof-of-concept data: reducing the risk of hospitalization in outpatient COVID-19 patients by 72%.

    • Last Update: 2020-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Lilly Announces New Coronavirus And Antibody Phase II Proof of Concept Data: Reducing 72% Risk of Hospitalization of Outpatient COVID-19 Patients Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube 2020-09-17 Share Lilly On September 16, 1999, Lilly announced the results of an interim analysis of the BLAZE-1 study, which showed that the treatment of COVID-19 outpatients using a single drug with the medium antibody LY-CoV555 reduced hospitalization rates.
    BLAZE-1 study is a randomized, double-blind, placebo-controlled Phase II conceptual validation study designed to assess the efficacy and safety of LY-CoV555 single-drug or combined LY-CoV016 treatment for outpatient COVID-19 patients with symptoms, and plans to recruit 800 subjects.
    452 newly diagnosed mild to moderate COVID-19 patients in the LY-CoV555 single-drug treatment group who tested the trial were given placebos and LY-CoV555 700mg, respectively. At 2800mg and 7000mg, the main endpoint is a change in viral load from baseline levels on the 11th day, and other endpoints include COVID-19-related hospitalization, emergency or death from the group to the 29th day.
    results showed that the 2800 mg dose level LY-CoV555 treatment reached the preset main endpoint, and the other dose groups did not reach the main endpoint.
    most patients, including the placebo group, were able to reach near-complete clearance of the virus on the 11th day.
    analysis of other virological data shows that LY-CoV555 can improve virus removal rates earlier (day 3) and reduce the proportion of patients with higher viral loads at subsequent points in time.
    these biomarker data are associated with the ability of LY-CoV555 to have a positive impact on COVID-19-related hospital or emergency endpoints.
    aggregate analysis data from each dose group found that the risk of hospitalization or emergency in patients treated with LY-CoV555 was 1.7% (5/302) and 6% (9/150) in the placebo group, suggesting that LY-CoV555 reduced the risk of hospitalization and emergency care in patients with mild to moderate COVID-19 by 72%.
    previous clinical studies have found risk factors such as age and BMI in patients hospitalized with COVID-19, suggesting that treatment options may be more effective in some high-risk groups, and the BLAZE-1 study supports this hypothesization.
    BLAZE-1 study, none of the patients in all treatment groups ( including the placebo group) progressed to mechanical aeration or died.
    exploratory analysis showed that LY-CoV555 treatment improved patients' symptoms faster than placebo, further supporting the conclusion that LY-CoV555 reduced hospitalization rates.
    LY-CoV555 tolerance is good and no adverse treatment-related events have been reported.
    -related emergency adverse events in each dose group were similar to between the placebo groups.
    RNA sequencing showed that LY-CoV555 drug-resistant variants occurred in both the placebo group and the various dose treatment groups, and that the drug resistance rate in the LY-CoV555 group was higher than in the placebo group (8% vs 6%).
    LY-CoV555 is an IgG1 monoclonal antibody developed by Lilly in collaboration with AbCellera for the treatment and prevention of COVID-19, which binds directly to SARS-CoV-2's prickly protein, blocking the virus from adhesion and entering human host cells, thus playing a role in meliaring the virus.
    Daniel Skovronsky, Chief Scientific Officer, Daniel Skovronsky, said: "The interim data from the BLAZE-1 trial suggest that LY-CoV555 is an antibody specifically designed for SARS-CoV-2 with direct antiviral effects that can reduce COVID-related hospitalization.
    results further strengthen our belief that meso-antibodies can help fight COVID-19.
    plans to publish the interim findings in peer-reviewed journals as soon as possible and discuss next steps with regulators around the world.
    BLAZE-1 clinical trials are still ongoing, including the evaluation of the effects of LY-CoV555 in a larger, high-risk patient queue in combination with another medium-level antibody, LY-CoV016, which binds to a different table of SARS-CoV-prick proteins, further confirming the benefits of these two antibody combinations in reducing the proportion of patients with sustained high viral load and the associated risk of hospitalization of COVID-19.
    Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Met Medical".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    reproduce content at the same time does not represent the position of this site.
    leave a message here.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.